I think your highlighted paragraph is about DCVax-D. Apparently DCVax-D can be semi allogeneic, that is a big deal patient and money wise. Very good news for longs.
I think you are getting your technologies mixed up.
AV. Barrel and scrape comes to mind.
By the way this was part of a planning application, and it wouldn't be LP if she didn't obscure things somewhat with a little smokescreen.
It comes with the territory I'm afraid.
LP's idiosyncratic way of operating is what it is. If that is of sufficient concern to a potential shareholder, then they should keep their money in their pocket.
Scaffold? Is that about taking organs not suitable for transplantation and repairing them with stem cells? That is a good idea, I did not know they were working on that?
On December 9, 2014, Aracaris Capital Ltd, a subsidiary of the Company in the UK, completed the purchase of the second portion of the property intended for the manufacturing expansion for DCVax products in the UK. This property is located within and surrounded by the first portion of the property already acquired by Aracaris, as previously reported. The purchase price for the additional property was £5 million (approximately $7.86 million). The additional property includes approximately 12 acres of potentially developable land (as well as non-developable land), and certain existing buildings. Development of the property for DCVax manufacturing will require approval by the Planning Commission to re-classify the property, removal of certain existing structures, making certain site improvements, Planning Commission approval of the intended use after re-classification, and Planning Commission approval of the specific designs and engineering. The Company plans to explore various structures and approaches for financing and/or development of the property that may enable the Company to withdraw its capital from the property. https://www.sec.gov/Archives/edgar/data/1072379/000114420414073984/v396605_8k.htm